As many of you know, I’m currently studying to become a Certified Diabetes Educator. So I was delighted to have the opportunity to attend the American Diabetes Association’s annual Advanced Postgraduate Course in New York City on Feb. 23 — a two-and-a-half-day conference that can be viewed as the ‘little sister’ to the ADA’s huge Scientific Sessions held each summer.
This Postgraduate event hosts just a few hundred doctors, pharmacists, diabetes educators, dieticians and other healthcare…
Read more »
It’s no surprise to our readers that one of the biggest issues with current diabetes management is the lag time of our current fast-acting insulins.
Although light years ahead of what patients had in the past, current fast-acting insulins still aren’t quite up to snuff to handle post-prandial spikes. This is becomes a barrier for developing an Artificial Pancreas, as the insulin can’t respond quickly enough to sensor data in a closed-loop system.
The topic…
Read more »
By
AmyT on
March 31, 2009
What is the biggest problem with treating Type 1 diabetes? The experts all say it’s that the insulins we have to inject simply aren’t fast enough; they don’t really mimic the effect of natural pancreas delivery because they take too long to kick in.
Several companies are rushing to solve this problem with the obvious: super-fast-acting insulin analogs, such as the relatively new Glulisine (aka Apidra), and BioDel’s ViaJect, currently being submitted for FDA review.…
Read more »
